Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Avapritinib improves overall symptoms, skin lesions and quality of life in patients with advanced systemic mastocytosis in the PATHFINDER study

Autor: Maurer, M., Siebenhaar, F., Hartmann, K., Reiter, A., Radia, D., Deininger, M. W., Sen, J., Lin, H., Mar, B. J., Gotlib, J., Deangelo, D. J., Broesby-Olsen, S.

Publikováno v: Maurer, M, Siebenhaar, F, Hartmann, K, Reiter, A, Radia, D, Deininger, M W, Sen, J, Lin, H, Mar, B J, Gotlib, J, Deangelo, D J & Broesby-Olsen, S 2021, ' Avapritinib improves overall symptoms, skin lesions and quality of life in patients with advanced systemic mastocytosis in the PATHFINDER study ', Allergy, vol. 76, no. Suppl. 110, pp. 22 . https://doi.org/10.1111/all.15094

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::f54eacec70afa60290a36fd30c2e09df
https://portal.findresearcher.sdu.dk/da/publications/5920ea15-883f-4f94-9938-7077dd39483b

Results from PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM)

Autor: Maurer, M., Elberink, H. O., Gotlib, J., Sabato, V., Hartmann, K., Broesby-Olsen, S., Castells, M., Deininger, M. W., Heaney, M. L., George, T. I., Siebenhaar, F., Radia, D., Triggiani, M., van Daele, P., Deangelo, D. J., Schmidt-Kittler, O., Lin, H. -M., Morrison, A., Mar, B., Akin, C.

Publikováno v: Maurer, M, Elberink, H O, Gotlib, J, Sabato, V, Hartmann, K, Broesby-Olsen, S, Castells, M, Deininger, M W, Heaney, M L, George, T I, Siebenhaar, F, Radia, D, Triggiani, M, van Daele, P, Deangelo, D J, Schmidt-Kittler, O, Lin, H-M, Morrison, A, Mar, B & Akin, C 2020, ' Results from PIONEER: A randomized, double-blind, placebo-controlled, phase 2 study of avapritinib in patients with indolent systemic mastocytosis (ISM) ', Oncology Research and Treatment, vol. 43, no. Suppl. 4, 384, pp. 77 . < https://doi.org/10.1159/000510995 >

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3062::b5e8e55a7cafacd6fadbeed0a103d6d7
https://portal.findresearcher.sdu.dk/da/publications/db60a38f-88ba-4565-abdc-02b4cbd50f7d

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia.

Autor: DeAngelo, D J¹, Stevenson, K E², Dahlberg, S E², Silverman, L B³, Couban, S⁴, Supko, J G⁵, Amrein, P C⁵, Ballen, K K⁵, Seftel, M D⁶, Turner, A R⁷, Leber, B⁸, Howson-Jan, K⁹, Kelly, K¹⁰, Cohen, S¹¹, Matthews, J H¹², Savoie, L¹³, Wadleigh, M¹, Sirulnik, L A¹, Galinsky, I¹, Neuberg, D S²

Publikováno v: Leukemia (08876924). Mar2015, Vol. 29 Issue 3, p526-534. 9p. 1 Diagram, 5 Charts, 2 Graphs.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts

Autor: Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, Oliver

Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b255920b78c8f42dc4e92fc9813e17ff
https://orca.cardiff.ac.uk/id/eprint/103058/1/leu2017159a.pdf